TranspireBio Announces Successful Completion of a Pivotal Phase 1 Study with its Proprietary Springboard™ Soft Mist Inhaler Platform
TranspireBio Announces Successful Completion of a Pivotal Phase 1 Study with its Proprietary Springboard™ Soft Mist Inhaler Platform SUNRISE, Fla., October 6, 2026 (PR NEWSWIRE) – TranspireBio Holdings Inc., an integrated U.S.-based clinical-stage, biopharmaceutical company advancing inhaled therapeutics for respiratory and systemic diseases, today announced the successful completion of a pivotal Phase 1 pharmacokinetic (PK) […]